
News|Articles|December 3, 2025
Accelerate Cell Line Development with GPEx® Lightning: Speed, Stability, and Industry-Leading Titers
Author(s)Catalent
Catalent’s GPEx® Lightning platform delivers stable, high-yield cell lines with unmatched speed—achieving titers up to 15g/L for mAbs and 11g/L for bispecifics. With 25-day pool generation and up to 12 weeks saved on development timelines, this offering sheet outlines key performance metrics and benefits that make GPEx® Lightning a game-changer for biologics developers.
Trending on Pharmaceutical Technology
1
PharmTech Weekly Roundup—June 5, 2026
2
A Pharma Manufacturing Blueprint from Delaware’s Innovation Vision
3
EMA Collaborates with African Regulators on Ebola Treatments
4
Renewing Prosaic Generics for Cancer Treatment
5